Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Valbiotis SAS (ALVAL)

Paris
Currency in EUR
Disclaimer
3.825
-0.050(-1.29%)
Real-time Data
ALVAL Scorecard
Fair Value
Unlock Value
Day's Range
3.6503.850
52 wk Range
2.8207.500
Prev. Close
3.875
Open
3.85
Day's Range
3.65-3.85
52 wk Range
2.82-7.5
Volume
13,374
Average Vol. (3m)
32,982
1-Year Change
1.17%
Shares Outstanding
15,772,550
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

5.58
ALCUR
-0.71%
0.6060
MHM
-0.66%
3.350
ALLEX
-1.18%
0.6060
ALSRS
-2.26%
How do you feel today about ALVAL?
Vote to see community's results!
or

Valbiotis SAS Company Profile

Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.